NRx Pharmaceuticals, Inc.
NRXP
$2.27
-$0.02-0.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -25.13M | -20.38M | -24.82M | -25.64M | -30.15M |
| Total Depreciation and Amortization | 5.00K | 5.00K | 5.00K | 5.00K | 5.00K |
| Total Amortization of Deferred Charges | 896.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.36M | 845.00K | 2.26M | 1.44M | 3.32M |
| Change in Net Operating Assets | 5.29M | 7.80M | 8.57M | 4.96M | 5.16M |
| Cash from Operations | -10.64M | -11.73M | -13.99M | -19.24M | -21.66M |
| Capital Expenditure | -- | 1.00K | -1.00K | 1.00K | -3.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 1.00K | -1.00K | 1.00K | -3.00K |
| Total Debt Issued | 7.08M | 3.10M | 157.00K | 943.00K | 943.00K |
| Total Debt Repaid | -8.58M | -6.07M | -6.10M | -6.19M | -4.04M |
| Issuance of Common Stock | 5.91M | 5.91M | 5.69M | 8.13M | 8.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 1.17M | 1.17M | 1.17M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.07M | 1.54M | -- | -- | -- |
| Cash from Financing | 7.49M | 4.47M | 919.00K | 4.05M | 6.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.15M | -7.26M | -13.07M | -15.19M | -15.46M |